Supplemental Digital Content 4. Clinical Features and Outcomes in Patients With Second Complete Responsea After Primary Treatment With VDC/IE
Chemotherapy
Patient
1
Site of Primary
Primary Therapy
Time to
ES/Age at
(VDC/IE
First
Site of
Diagnosis, y
Interval)
Relapse, mo
Relapse
Chest wall/23
Surgery (every 3
21
wk)
Time to
Local and
lung
Salvage Strategy
Topotecan and
Second
Status at Last
PRS,
Relapse, mo
Follow-Up
mob
12
Alive with disease
25
13
Alive without
92
cyclophosphamide
for 2 cycles, then
surgical resection
2
Sacrum/19
RT (every 3 wk)
53
Lungs
Ifosfamide and
doxorubicin before
disease; had 3
and after resection of
additional
lung nodules
resections and lung
RT
3
2nd
metatarsal/42
Surgery, RT
(every 3 wk)
27
Skull
Surgery and RT
20
Died of disease;
multiple bony
relapses
55
Supplemental Digital Content 4 (continued)
Patient
4
Site of Primary
Primary Therapy
Time to
ES/Age at
(VDC/IE
First
Site of
Diagnosis, y
Interval)
Relapse, mo
Relapse
Ulna/26
Surgery (every 3
12
Time to
Local
wk)
5
Erector spinae
muscle/43
Surgery (every 2
Salvage Strategy
Surgery (refused
Second
Status at Last
PRS,
Relapse, mo
Follow-Up
mob
Unk
chemo and RT)
21
Lung
wk)
Irinotecan,
Died; refused
40
follow-up
10
Died with disease
32
…
Alive without
17
temozolomide, and
lung RT
6
Paraspinous area
RT (every 2 wk)
40
Local
next to thoracic
IE before and after
resection
disease
spine/29
7
Distal
humerus/25
Limb-sparing
29
Local
Vincristine,
14
Alive with disease;
surgery (every 2
actinomycin D,
multiple lung
wk)
cyclophosphamide,
relapses with
alt with IE, and
resection and lung
amputation
RT, receiving
chemo
22
Supplemental Digital Content 4 (continued)
Patient
8
Site of Primary
Primary Therapy
Time to
ES/Age at
(VDC/IE
First
Site of
Diagnosis, y
Interval)
Relapse, mo
Relapse
Chest wall/25
Surgery (every 3
46
Time to
Local
wk)
Salvage Strategy
RT to mass, then
Second
Status at Last
PRS,
Relapse, mo
Follow-Up
mob
15
Alive with disease;
surgery, then
lung nodules
adjuvant
resected, then
temozolomide
clinical trial, then
76
resection and RT
for thoracic spine
relapse
9
Proximal
humerus/34
Surgery (every 2
wk)
31
Lungs
Irinotecan and
15
Alive with disease;
temozolomide before
lung nodules, in
and after lung RT
clinical trial with
figitumumab and
pegvisomant
28
Supplemental Digital Content 4 (continued)
Patient
10
Site of Primary
Primary Therapy
Time to
ES/Age at
(VDC/IE
First
Site of
Diagnosis, y
Interval)
Relapse, mo
Relapse
Chest/42
Surgery (every 2
21
wk)
Time to
T3-T6
Second
Status at Last
PRS,
Salvage Strategy
Relapse, mo
Follow-Up
mob
RT
5
vertebrae
Died with disease;
17
multiple lung mets,
cyclophosphamide/
topotecan, then
irinotecan/
temozolomide
11
Skull/38
Surgery (every 3
wk)
17
Local
RT
10
Died with disease;
multiple bony
recurrences treated
with RT, then softtissue and nodal
disease
29
Supplemental Digital Content 4 (continued)
Abbreviations: alt, alternating; chemo, chemotherapy; ES, Ewing sarcoma; IE, ifosfamide and etoposide; mets, metastases; PRS, postrelapse survival;
RT, radiotherapy; Unk, unknown; VDC, vincristine, doxorubicin, cyclophosphamide.
a
No disease at completion of first salvage therapy.
b
To last follow-up or death.